AGM/EGMAug 7, 2026, 09:12 AM
RedHill Biopharma AGM Approves CEO, Board Re-elections, Auditor
AI Summary
RedHill Biopharma Ltd. announced that all resolutions proposed at its adjourned Annual General Meeting of Shareholders on August 7, 2026, were duly approved. Key approvals included the re-appointment of Kesselman & Kesselman as auditors, the re-election of two board members, and the engagement of Mr. Dror Ben-Asher as Chairman and CEO. Additionally, shareholders approved an amendment to the Company's Articles of Association to eliminate the par value of its shares.
Key Highlights
- Shareholders re-appointed Kesselman & Kesselman (PricewaterhouseCoopers) as auditors for 2026 until the next AGM.
- Mr. Rick D. Scruggs and Dr. Shmuel Cabilly were re-elected to the Board of Directors for a three-year term until 2029.
- Mr. Dror Ben-Asher's engagement as Chairman of the Board and Chief Executive Officer was approved.
- The Company's Articles of Association were amended to eliminate the par value of its shares.
Price Impact
More from RDHL